Hepatitis C News

WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.

Healio spoke with Meg Doherty, MD, MPH, PhD, Director Global HIV, Hepatitis and STI Programmes at WHO, about elimination efforts for hepatitis D, including how hepatitis D would be affected by WHO Global Hepatitis Elimination goals and what U.S. physician can do to help work towards hepatitis elimination.

People with HIV and untreated hepatitis C virus have an 85% higher risk for type 1 MI per each 10-year increase in age, researchers reported.

Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according to data published in Cell Metabolism.

New data from a CDC Vital Signs report show that less than one-third of people with hepatitis C receive treatment within 1 year of their diagnosis despite the availability of direct-acting antivirals.

Healio presents the top peer-tested articles from June, which include updates on the acute hepatitis outbreak in children, FDA approval of Skyrizi for Crohn’s disease, investigational care of patients with chronic constipation and more.

LONDON —Although progress has been made, nearly 12 million individuals will die early from preventable hepatitis B and hepatitis C deaths without additional interventions, according to research presented at the International Liver Congress.

LONDON — Noninvasive testing may predict clinically significant portal hypertension and other outcomes in patients after hepatitis C virus cure, according to research presented at the International Liver Congress.

Following updated hepatitis C virus screening recommendations issued in 2020, HCV screening in pregnancy accelerated across the country, according to a retrospective cohort study published in Obstetrics & Gynecology.

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased risk for arrhythmias and conduction disorders.